key: cord-0704651-n9imgkhx
authors: Ruhnau, Johannes; Grote, Valerian; Juarez-Osorio, Mariana; Bruder, Dunja; Rapp, Erdmann; Rexer, Thomas F. T.; Reichl, Udo
title: Cell-free glycoengineering of the recombinant SARS-CoV-2 spike glycoprotein
date: 2021-04-30
journal: bioRxiv
DOI: 10.1101/2021.04.30.442139
sha: 85a414ba1c45092e139aec80dd6a543354cbb0a9
doc_id: 704651
cord_uid: n9imgkhx

The baculovirus-insect cell expression system is readily utilized to produce viral glycoproteins for research as well as for subunit vaccines and vaccine candidates, for instance against SARS-CoV-2 infections. However, the glycoforms of recombinant proteins derived from this expression system are inherently different from mammalian cell-derived glycoforms with mainly complex-type N-glycans attached, and the impact of these differences in protein glycosylation on the immunogenicity is severely underinvestigated. This applies also to the SARS-CoV-2 spike glycoprotein, which is the antigen target of all licensed vaccines and vaccine candidates including virus like particles and subunit vaccines that are variants of the spike protein. Here, we expressed the transmembrane-deleted human β-1,2 N-acetlyglucosamintransferases I and II (MGAT1∆TM and MGAT2∆TM) and the β-1,4-galactosyltransferase (GalT∆TM) in E. coli to in-vitro remodel the N-glycans of a recombinant SARS-CoV-2 spike glycoprotein derived from insect cells. In a cell-free sequential one-pot reaction, fucosylated and afucosylated paucimannose-type N-glycans were converted to complex-type galactosylated N-glycans. In the future, this in-vitro glycoengineering approach can be used to efficiently generate a wide range of N-glycans on antigens considered as vaccine candidates for animal trials and preclinical testing to better characterize the impact of N-glycosylation on immunity and to improve the efficacy of protein subunit vaccines.

1999; Dalziel et al., 2014; Varki, 2017) . Furthermore, glycosylation plays a major role for 

Especially the latter is a major hurdle for vaccine design. The mode of actions that are known 67 to be employed to invade the immune system are secretion and shedding of glycoproteins that 68 function as a decoy to the immune system, and the shielding of epitopes (Watanabe et al., 2019) .

The latter is facilitated by occluding antigenic epitopes with host-derived glycans that are 70 obtained through hijacking the host's cellular glycosylation machinery (Pralow et al.; Schwarzer 71 et al., 2009; Francica et al., 2010; Helle et al., 2011; Rödig et al., 2011; Rödig et al., 72 2013; Sommerstein et al., 2015; Behrens et al., 2016; Gram et al., 2016; Walls et al., 2016) . 73 Moreover, it has been shown that also the glycoform itself can have an impact on binding and 74 transmission assay as well as on transmissibility, antigenicity, and immunogenicity in animal 75 models (Lin et al., 2003; Hütter et al., 2013; Chen et al., 2014; Li et al., 2016; Go et al., 2017) . 76 While it is assumed that immunogenic antigens benefit from mimicking the glycosylation of 77 host cell proteins, it has also been proposed that modification of specific terminal sugar residues 78 could be used to amplify vaccine efficacy (Galili, 2020; Chen, 2021) . However, due to the 79 complexity of protein glycosylation and the prevailing lack of methods to introduce defined virus (Walls et al., 2020) . Its membrane envelope consists of three membrane proteins: the 85 surface spike (S) glycoprotein, an integral membrane protein and an envelope protein (Wan et 86 al., 2020; Zhou et al., 2020) . Virus entry into human host cells is mediated by the S glycoprotein 87 that binds to angiotensin-converting enzyme 2 (Walls et al., 2020) . The S protein has 22 88 N-linked glycosylation sites. Thus, it is significantly more glycosylated than, for instance, the 89 influenza A hemagglutinin Briefly, 0.9 cm cotton rope was used for Cotton HILIC SPE. The stationary phase was 167 equilibrated with 50 µL LC-MS grade H2O followed by 50 µL 85% ACNaq. 10 µL of released 168 N-glycans were adjusted to 70 µL 85% ACNaq with 1% TFA and loaded onto the HILIC phase.

Following 2 washing steps with 50 µL 85% ACNaq with 1% TFA and 50 µL 85% ACNaq, the spike protein, human cell-derived spike proteins also exhibit complex-type multi-antennary and 295 sialylated structures (Watanabe et al., 2020) . Taken together, a significant overlap of the 296 glycoform has been generated. Whether the overlap is also site-specific remains to be 297 investigated in future.

Over the past years, many efforts have been made to engineer insect cell lines to express 

An interactive website 493 tracking COVID-19 vaccine development

Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted 498 Infection

Mannosyl (alpha-1,3-)-glycoprotein beta-1

NAcetylglucosaminyltransferase (MGAT1)

N-Glycans

Implementation of GlycanBuilder to draw a wide variety of 508 ambiguous glycans

Customized protein 510 glycosylation to improve biopharmaceutical function and targeting

Biological roles of glycans

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Glycan shield and epitope masking of a coronavirus spike 518 protein observed by cryo-electron microscopy

Receptor Recognition by the

Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural 522 Studies of SARS Coronavirus

Site-specific 525 glycan analysis of the SARS-CoV-2 spike

Exploitation of 527 glycosylation in enveloped virus pathobiology

General Subjects 1863

Cryo-EM structure of the 2019-nCoV spike in the prefusion 531 conformation

A vaccine targeting the RBD of the S 542 protein of SARS-CoV-2 induces protective immunity

A pneumonia 547 outbreak associated with a new coronavirus of probable bat origin

Table 1. N-glycan categories and nomenclature for all detected and referenced structures with 553 the exception of oligomannose-type N-glycans. The monosaccharide building blocks are 554 mannose (green circle), GlcNAc (blue square), fucose (red triangle) and galactose (yellow

MGAT1ΔTM. C) 12 h after the addition of MGAT2ΔTM. D) 12 h after the addition of 583

Only the peaks that depict N-glycans are annotated

Geisler, C., Mabashi-Asazuma, H., and Jarvis, D.L. (2015) . "An overview and history of 392 glyco-engineering in insect expression systems," in Glyco-Engineering: Methods and 393 Protocols.), 131-152. 394 Go, E.P., Ding, H., Zhang, S., Ringe, R.P., Nicely, N., Hua, D., Steinbock, R.T., Golabek, M., 395 Alin, J., Alam, S.M., Cupo, A., Haynes, B.F., Kappes, J.C., Moore, J.P., Sodroski, Neelamegham, S., Aoki-Kinoshita, K., Bolton, E., Frank, M., Lisacek, F., Lütteke, T., 447